Canadian researchers conducted a Phase III randomized trial involving 461 adults with inadequately controlled type 2 diabetes and found that those who received ertugliflozin 5mg/day or 15mg/day experienced a -0.9% and a -1% mean change in glycated HbA1C from baseline to week 52, respectively, compared with the placebo group. The findings in Diabetes, Obesity and Metabolism revealed that the ertugliflozin group also had reductions in fasting plasma glucose, systolic blood pressure and body weight.